Medicine and Dentistry
Overactive Bladder
100%
Lower Urinary Tract Symptom
30%
Botulinum Toxin A
28%
Bladder
26%
Metabolic Syndrome
19%
Water Birth
19%
Pelvic Organ Prolapse
19%
Retrospective Study
19%
Pelvic Floor
19%
Cystalgia
19%
Self-Diagnosis
19%
Mirabegron
19%
Solifenacin
19%
Neuromodulation
19%
Spinal Cord Injury
19%
Placebo
19%
Patient-Reported Outcome
19%
Monotherapy
19%
Interstitial Cystitis
14%
Quality of Life
11%
Conservative Treatment
10%
Perineum Injury
10%
Autonomic Nervous System
9%
Cardiovascular System
9%
Bladder Emptying
9%
Hyperinsulinemia
9%
Pelvis
9%
Prostate Hypertrophy
9%
Erectile Dysfunction
9%
Sacral Nerve Stimulation
9%
Randomized Controlled Trial
9%
Nursing and Health Professions
Overactive Bladder
43%
Patient-Reported Outcome
38%
Lower Urinary Tract Symptom
31%
Quality of Life
30%
Water Birth
19%
Content Validity
19%
Solifenacin
19%
Mirabegron
19%
Monotherapy
19%
Self Evaluation
19%
Placebo
19%
Incontinence
16%
Perineum Injury
10%
Adverse Event
6%
Health Economics
6%
Outcome Assessment
6%
Health Outcomes
6%
Urine Incontinence
5%
Enuresis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Overactive Bladder
76%
Botulinum Toxin A
28%
Lower Urinary Tract Symptom
28%
Mirabegron
19%
Fesoterodine
19%
Solifenacin
19%
Pelvic Organ Prolapse
19%
Monotherapy
19%
Placebo
19%
Spinal Cord Injury
19%
Randomized Controlled Trial
9%
Adverse Event
6%
Deterioration
5%
